Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

<p>Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Jonathan Chou (14957015) (author)
Otros Autores:	Emily A. Egusa (14962343) (author), Sinan Wang (14962346) (author), Michelle L. Badura (14962349) (author), Fei Lee (14962352) (author), Anil P. Bidkar (14962355) (author), Jun Zhu (14962358) (author), Tanushree Shenoy (14957003) (author), Kai Trepka (14962361) (author), Troy M. Robinson (14962364) (author), Veronica Steri (14962367) (author), Jiaoti Huang (14962370) (author), Yuzhuo Wang (14962373) (author), Eric J. Small (14962376) (author), Emily Chan (14962379) (author), Bradley A. Stohr (14962382) (author), Alan Ashworth (14957030) (author), Brant Delafontaine (14962385) (author), Sylvie Rottey (14962388) (author), Keegan S. Cooke (14962391) (author), Nooshin Hashemi Sadraei (14962394) (author), Brian Yu (14962397) (author), Mark Salvati (14962400) (author), Julie M. Bailis (14962403) (author), Felix Y. Feng (14845891) (author), Robert R. Flavell (9563200) (author), Rahul Aggarwal (14960826) (author)
Publicado:	2025
Materias:	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

_version_	1849927639654989824
author	Jonathan Chou (14957015)
author2	Emily A. Egusa (14962343) Sinan Wang (14962346) Michelle L. Badura (14962349) Fei Lee (14962352) Anil P. Bidkar (14962355) Jun Zhu (14962358) Tanushree Shenoy (14957003) Kai Trepka (14962361) Troy M. Robinson (14962364) Veronica Steri (14962367) Jiaoti Huang (14962370) Yuzhuo Wang (14962373) Eric J. Small (14962376) Emily Chan (14962379) Bradley A. Stohr (14962382) Alan Ashworth (14957030) Brant Delafontaine (14962385) Sylvie Rottey (14962388) Keegan S. Cooke (14962391) Nooshin Hashemi Sadraei (14962394) Brian Yu (14962397) Mark Salvati (14962400) Julie M. Bailis (14962403) Felix Y. Feng (14845891) Robert R. Flavell (9563200) Rahul Aggarwal (14960826)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Jonathan Chou (14957015) Emily A. Egusa (14962343) Sinan Wang (14962346) Michelle L. Badura (14962349) Fei Lee (14962352) Anil P. Bidkar (14962355) Jun Zhu (14962358) Tanushree Shenoy (14957003) Kai Trepka (14962361) Troy M. Robinson (14962364) Veronica Steri (14962367) Jiaoti Huang (14962370) Yuzhuo Wang (14962373) Eric J. Small (14962376) Emily Chan (14962379) Bradley A. Stohr (14962382) Alan Ashworth (14957030) Brant Delafontaine (14962385) Sylvie Rottey (14962388) Keegan S. Cooke (14962391) Nooshin Hashemi Sadraei (14962394) Brian Yu (14962397) Mark Salvati (14962400) Julie M. Bailis (14962403) Felix Y. Feng (14845891) Robert R. Flavell (9563200) Rahul Aggarwal (14960826)
author_role	author
dc.creator.none.fl_str_mv	Jonathan Chou (14957015) Emily A. Egusa (14962343) Sinan Wang (14962346) Michelle L. Badura (14962349) Fei Lee (14962352) Anil P. Bidkar (14962355) Jun Zhu (14962358) Tanushree Shenoy (14957003) Kai Trepka (14962361) Troy M. Robinson (14962364) Veronica Steri (14962367) Jiaoti Huang (14962370) Yuzhuo Wang (14962373) Eric J. Small (14962376) Emily Chan (14962379) Bradley A. Stohr (14962382) Alan Ashworth (14957030) Brant Delafontaine (14962385) Sylvie Rottey (14962388) Keegan S. Cooke (14962391) Nooshin Hashemi Sadraei (14962394) Brian Yu (14962397) Mark Salvati (14962400) Julie M. Bailis (14962403) Felix Y. Feng (14845891) Robert R. Flavell (9563200) Rahul Aggarwal (14960826)
dc.date.none.fl_str_mv	2025-11-24T22:44:16Z
dc.identifier.none.fl_str_mv	10.1158/0008-5472.30699465
dc.relation.none.fl_str_mv	https://figshare.com/articles/media/Supplementary_MovieS2b_from_Immunotherapeutic_Targeting_and_PET_Imaging_of_DLL3_in_Small-Cell_Neuroendocrine_Prostate_Cancer/30699465
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
dc.title.none.fl_str_mv	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
dc.type.none.fl_str_mv	Dataset Media info:eu-repo/semantics/publishedVersion dataset
description	<p>Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a.22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b.22Rv1, SHP-77, and T cells co-cultured with AMG 757. c.22Rv1, SHP-77, and T cells co-cultured with AMG 160.</p>
eu_rights_str_mv	openAccess
id	Manara_0c0550585348272ac841e859e0eff493
identifier_str_mv	10.1158/0008-5472.30699465
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30699465
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate CancerJonathan Chou (14957015)Emily A. Egusa (14962343)Sinan Wang (14962346)Michelle L. Badura (14962349)Fei Lee (14962352)Anil P. Bidkar (14962355)Jun Zhu (14962358)Tanushree Shenoy (14957003)Kai Trepka (14962361)Troy M. Robinson (14962364)Veronica Steri (14962367)Jiaoti Huang (14962370)Yuzhuo Wang (14962373)Eric J. Small (14962376)Emily Chan (14962379)Bradley A. Stohr (14962382)Alan Ashworth (14957030)Brant Delafontaine (14962385)Sylvie Rottey (14962388)Keegan S. Cooke (14962391)Nooshin Hashemi Sadraei (14962394)Brian Yu (14962397)Mark Salvati (14962400)Julie M. Bailis (14962403)Felix Y. Feng (14845891)Robert R. Flavell (9563200)Rahul Aggarwal (14960826)CancerTherapeutic Research and DevelopmentImmuno-oncologyMethods and TechnologyDrug TargetsCell surface receptor drug targetsGenitourinary CancersProstate cancerImagingPositron emission tomography (PET)ImmunotherapyPreclinical ModelsXenograft models<p>Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a.22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b.22Rv1, SHP-77, and T cells co-cultured with AMG 757. c.22Rv1, SHP-77, and T cells co-cultured with AMG 160.</p>2025-11-24T22:44:16ZDatasetMediainfo:eu-repo/semantics/publishedVersiondataset10.1158/0008-5472.30699465https://figshare.com/articles/media/Supplementary_MovieS2b_from_Immunotherapeutic_Targeting_and_PET_Imaging_of_DLL3_in_Small-Cell_Neuroendocrine_Prostate_Cancer/30699465CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/306994652025-11-24T22:44:16Z
spellingShingle	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer Jonathan Chou (14957015) Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
status_str	publishedVersion
title	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
title_full	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
title_fullStr	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
title_full_unstemmed	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
title_short	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
title_sort	Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
topic	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Ejemplares similares